3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Interventions
Abiraterone Acetate
3
Paclitaxel
2
sipuleucel-T
1
rucaparib
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
gallium 68 PSMA-11
1
apalutamide
1
abiraterone
1
Suspensions
1
Powders
1
Pluvicto
1
Leuprolide
1
Imatinib Mesylate
1
EPI-506
1
BAY 86-7548
1
Androgen Antagonists
1
Adrenal Cortex Hormones
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Genital Neoplasms, Male
×
Pluvicto
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled